Physician
Retina Consultants, LLP
Retina Consultants, LLP was paid $6.55M by Medicaid between Jan 2018 and Nov 2024, across 16 billing codes. Its largest line is J0178, Injection, aflibercept, 1 mg — 72% of everything it billed.
33Billing provider infoRETINA CONSULTANTS, LLP
SALEM, OR 97302
SALEM, OR 97302
33aNPI1528181674assigned 04/06/2007
33bProvider typeOphthalmology Physician
28Total paid$6.55M
24GClaims42,576
24DCodes billed16
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Ophthalmology Physician providers in Oregon
Rank by total paid#2 of 50
Median peer was paid$25K
This provider vs. median264×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,063 | $346K | |
| 2019 | 7,427 | $1.18M | |
| 2020 | 5,629 | $758K | |
| 2021 | 5,907 | $960K | |
| 2022 | 6,413 | $1.22M | |
| 2023 | 6,604 | $1.07M | |
| 2024incomplete | 6,533 | $1.01M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 72% | 4,843 | 3,485 | $4.69M |
| 67028 | Intravitreal injection of a pharmacologic agent | 11% | 12,436 | 10,172 | $717K |
| 92134 | 4.5% | 13,688 | 11,586 | $298K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 4.4% | 4,404 | 3,573 | $285K |
| J9035 | Injection, bevacizumab, 10 mg | 3.6% | 2,962 | 2,384 | $237K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | 1.2% | 1,683 | 1,350 | $81K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.1% | 1,124 | 1,011 | $69K |
| J2777 | Injection, faricimab-svoa, 0.1 mg | 1.0% | 44 | 40 | $68K |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | <1% | 40 | 40 | $39K |
| J7999 | Compounded drug, not otherwise classified | <1% | 519 | 423 | $22K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | <1% | 153 | 144 | $17K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | <1% | 256 | 227 | $12K |
4 more codes
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSHEETS, TERI (CEO)